Loading viewer...
other
Format: PDF other
Plainview LLC short-seller report from October 2018 arguing that Nektar Therapeutics' NKTR-214 immunotherapy candidate lacks efficacy and misses clinical thresholds. The report claims the drug's mechanism does not achieve stated objectives and compares results unfavorably to competing candidates like epacadostat.
conference
28 Pages
other
91 Pages
CNP Assurances
other
31 Pages
ΤΙΤΑΝ
Alliant International University 2024 Business Administration Performance Fact Sheet
otherother
1173 Pages
Alliant International University
ADP 1997 Annual Meeting Proxy Statement
otherother
22 Pages
Automatic Data Processing